


In the Claims:

1. (Previously Presented) A compound of the formula (I)



in which

A is an aromatic heteromonocyclic, or an aromatic or partially aromatic heterobicyclic ring,

10 where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups, where not more than one of the heteroatoms is an oxygen atom,

15 and A may be substituted by radicals R¹¹, R¹² and/or R¹³,

where

20 R¹¹, R¹² and R¹³ at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

25 R³ and R⁴ are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂, or

R³ and R⁴ are connected to give -CH=CH-CH=CH-, -(CH₂)₄- or -(CH₂)₃-,

R⁵ is a radical (W)-(X)-(Y)-Z, where

5 W is selected from the group consisting of C₁-C₄-alkylen, C₂-C₄-alkenylen, C₂-C₄-alkynylen, O, O-(C₁-C₄-alkylen), S, S-(C₁-C₄-alkylen), NR⁵⁴, NR⁵⁴-(C₁-C₄-alkylen) and a bond,

X is selected from the group consisting of CO, CO-O, SO₂, NR⁵⁴, NR⁵⁴-CO, NR⁵⁴-SO₂, CO-NR⁵⁸ and a bond,

Y is C₁-C₆-alkylen, C₂-C₆-alkenylen, C₂-C₆-alkynylen, or a bond,

10 Z is selected from the group consisting of hydrogen, E, O-R⁵², NR⁵¹R⁵², S-R⁵², where

E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, said ring may comprise up to two oxo groups, and 15 may be substituted by radicals R⁵⁵, R⁵⁶, R⁵⁷, and/or up to three radicals R⁵³,

20 R⁵¹ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁵³,

25 R⁵² at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, E and C₁-C₄-alkylen-E,

30 R⁵³ at each occurrence is independently selected from the group consisting of hydrogen chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

35 R⁵⁴ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁵⁹,

40 R⁵⁵ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₄-alkylen-phenyl, 45 where the ring may be substituted by up to two radicals R⁶⁰, and OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

R^{56} is a group $Q^1-Q^2-Q^3$, where

Q^1 is selected from the group consisting of a bond, C_1-C_4 -alkylen, C_2-C_4 -alkenylen, C_2-C_4 -alkynylen, C_1-C_4 -alkylen- $N(C_1-C_4$ -alkyl), $N(C_1-C_4$ -alkyl), C_1-C_4 -alkylen- NH , $N(C_1-C_4$ -alkyl)- C_1-C_4 -alkylen, $NH-C_1-C_4$ -alkylen, O , C_1-C_4 -alkylen- O , $O-C_1-C_4$ -alkylen, $CO-NH$, $CO-N(C_1-C_4$ -alkyl), $NH-CO$, $N(C_1-C_4$ -alkyl)- CO , CO , SO_2 , SO , S , O , SO_2-NH , $SO_2-N(C_1-C_4$ -alkyl), $NH-SO_2$, $N(C_1-C_4$ -alkyl)- SO_2 , $O-CO-NH$, $O-CO-N(C_1-C_4$ -alkyl), $NH-CO-O$, $N(C_1-C_4$ -alkyl)- $CO-O$, $N(C_1-C_4$ -alkyl)- $CO-N(C_1-C_4$ -alkyl), $NH-CO-N(C_1-C_4$ -alkyl), $N(C_1-C_4$ -alkyl)- $CO-NH$, and $NH-CO-NH$,

10

Q^2 is selected from the group consisting of C_1-C_4 -alkylen, C_2-C_4 -alkenylen, C_2-C_4 -alkynylen, and a bond,

15

Q^3 is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups and may be substituted by the radicals R^{63} , R^{64} and/or R^{65} ,

20

R^{57} at each occurrence is independently selected from the group consisting of hydrogen, C_1-C_6 -alkyl, phenyl, C_1-C_4 -alkylen-phenyl, $COOH$, $CO-O-C_1-C_4$ -alkyl, $CONH_2$, $CO-NH-C_1-C_4$ -alkyl, $CO-N(C_1-C_4$ -alkyl)₂, $CO-C_1-C_4$ -alkyl, CH_2-NH_2 , $CH_2-NH-C_1-C_4$ -alkyl and $CH_2-N(C_1-C_4$ -alkyl)₂,

25

R^{58} at each occurrence is independently selected from the group consisting of hydrogen, C_1-C_6 -alkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, phenyl and C_1-C_4 -alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R^{62} ,

30

R^{59} , R^{60} and R^{62} at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN , CF_3 , OCF_3 , NO_2 , OH , $O-C_1-C_4$ -alkyl, C_1-C_6 -alkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, NH_2 , $NH(C_1-C_4$ -alkyl) and $N(C_1-C_4$ -alkyl)₂,

35

R^{63} , R^{64} and R^{65} at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN , CF_3 , OCF_3 , NO_2 , OH , $O-C_1-C_4$ -alkyl, O -phenyl, $O-C_1-C_4$ -alkylen-phenyl, phenyl, C_1-C_6 -alkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, NH_2 , $NH(C_1-C_4$ -alkyl) and $N(C_1-C_4$ -alkyl)₂,

R^6 and R^7 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF_3 , OCF_3 , NO_2 , OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,


5

and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof.

2. (Previously Presented) The compound of claim 1, wherein A is selected from the group consisting of aromatic heteromonocyclic and aromatic heterobicyclic systems 10 comprising 1 or 2 heteroatoms, where one of the 2 heteroatoms is nitrogen.

3. (Previously Presented) The compound of claim 1, wherein A is selected from the group consisting of benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, 15 quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan.

4. (Previously Presented) A compound of the formula (II)



20 in which

B is selected from the group consisting of thiophene, furan, pyrrole, pyridine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, dihydrobenzofuran, indole, dihydroisoindole,

25

an aromatic heteromonocyclic and an aromatic or partially aromatic heterobicyclic ring,

where the heterocycles are 5- or 6-membered rings and comprise 2 to 4 heteroatoms

selected from the group consisting of N, O and S, and up to 2 oxo groups, and

B may be substituted by the radicals R²¹, R²² and/or R²³,

5 R²¹, R²² and R²³ at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂, morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-piperazin-1-yl, 4-(C₁-C₄-alkyl)-piperazin-1-yl,

10 10 R³ and R⁴ are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂, or

15 15 R³ and R⁴ are connected to give -CH=CH-CH=CH-, -(CH₂)₄- or -(CH₂)₃-,

R⁵ is a radical (W)-(X)-(Y)-Z, where

20 20 W is selected from the group consisting of C₁-C₄-alkylen, C₂-C₄-alkenylen, C₂-C₄-alkynyl, O, O-(C₁-C₄-alkylen), S, S-(C₁-C₄-alkylen), NR⁵⁴, NR⁵⁴-(C₁-C₄-alkylen) and a bond,

X is selected from the group consisting of CO, CO-O, SO₂, NR⁵⁴, NR⁵⁴-CO, NR⁵⁴-SO₂, CO-NR⁵⁸ and a bond,

25 25 Y is C₁-C₆-alkylen, C₂-C₆-alkenylen, C₂-C₆-alkynyl, or a bond,
Z is selected from the group consisting of hydrogen, E, O-R⁵², NR⁵¹R⁵², S-R⁵², where

30 30 E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, said ring may comprise up to two oxo groups, and may be substituted by radicals R⁵⁵, R⁵⁶, R⁵⁷ and/or up to three radicals R⁵³ and,

35 35 R⁵¹ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁵³,

R⁵² at each occurrence is independently selected from the group consisting of

hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, E and C₁-C₄-alkylen-E,

R⁵³ at each occurrence is independently selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

R⁵⁴ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁵⁹,

R⁵⁵ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₄-alkylen-phenyl, where the ring may be substituted by up to two radicals R⁶⁰, and OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

R⁵⁶ is a group Q¹-Q²-Q³, where

Q¹ is selected from the group consisting of a bond, C₁-C₄-alkylen, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-alkylen-N(C₁-C₄-alkyl), N(C₁-C₄-alkyl), C₁-C₄-alkylen-NH, NH, N(C₁-C₄-alkyl)-C₁-C₄-alkylen, NH-C₁-C₄-alkylen, O, C₁-C₄-alkylen-O, O-C₁-C₄-alkylen, CO-NH, CO-N(C₁-C₄-alkyl), NH-CO, N(C₁-C₄-alkyl)-CO, CO, SO₂, SO, S, O, SO₂-NH, SO₂-N(C₁-C₄-alkyl), NH-SO₂, N(C₁-C₄-alkyl)-SO₂, O-CO-NH, O-CO-N(C₁-C₄-alkyl), NH-CO-O, N(C₁-C₄-alkyl)-CO-O, N(C₁-C₄-alkyl)-CO-N(C₁-C₄-alkyl), NH-CO-N(C₁-C₄-alkyl), N(C₁-C₄-alkyl)-CO-NH, and NH-CO-NH,

Q² is selected from the group consisting of C₁-C₄-alkylen, C₂-C₄-alkenyl, C₂-C₄-alkynyl, and a bond,

Q³ is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups and may be substituted by the radicals R⁶³, R⁶⁴ and/or R⁶⁵,

R⁵⁷ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, phenyl, C₁-C₄-alkylen-phenyl, COOH, CO-O-C₁-C₄-alkyl, CONH₂, CO-NH-C₁-C₄-alkyl, CO-N(C₁-C₄-alkyl)₂, CO-C₁-C₄-alkyl, CH₂-NH₂,

CH₂-NH-C₁-C₄-alkyl and CH₂-N(C₁-C₄-alkyl)₂,

R⁵⁸ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁶²;

R⁵⁹, R⁶⁰ and R⁶² at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,


R⁶³, R⁶⁴ and R⁶⁵ at each occurrence are independently selected of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

R⁶ and R⁷ at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof.

5. (Previously Presented) The compound of claim 4, wherein B is selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline.

6. (Previously Presented) A compound of the formula (III),



in which

D is an aromatic heteromonocyclic, or an aromatic or partially aromatic heterobicyclic ring,

5

where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups,

and D may be substituted by radicals R²¹, R²² and/or R²³,

10

G is an aromatic heteromonocyclic, aromatic or partially aromatic heterobicyclic ring,

where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups and

15

G may be substituted by radicals R⁷¹, R⁷² and/or R⁷³,

R²¹, R²², R²³, R⁷¹, R⁷² and R⁷³ at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂, morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-piperazin-1-yl, 4-(C₁-C₄-alkyl)-piperazin-1-yl,

25

R³ and R⁴ at each occurrence are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂, or

R³ and R⁴ are connected to give -CH=CH-CH=CH-, -(CH₂)₄- or -(CH₂)₃-,

R⁵ is a radical (W)-(X)-(Y)-Z, where

5 W is selected from the group consisting of C₁-C₄-alkylen, C₂-C₄-alkenylen, C₂-C₄-alkynyl, O, O-(C₁-C₄-alkylen), S, S-(C₁-C₄-alkylen), NR⁵⁴, NR⁵⁴-(C₁-C₄-alkylen) and a bond,

X is selected from the group consisting of CO, CO-O, SO₂, NR⁵⁴, NR⁵⁴-CO, NR⁵⁴-SO₂, CO-NR⁵⁸ and a bond,

10 Y is C₁-C₆-alkylen, C₂-C₆-alkenylen, C₂-C₆-alkynyl, or a bond,

Z is selected from the group consisting of hydrogen, E, O-R⁵², NR⁵¹R⁵², S-R⁵², where

15 E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups, and E may be substituted by radicals R⁵⁵, R⁵⁶, R⁵⁷ and/or up to three radicals R⁵³,

20 R⁵¹ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁵³,

R⁵² at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, E and C₁-C₄-alkylen-E,

25 R⁵³ at each occurrence is independently selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF₃, OCF₃, NO₂, OH, O-C₁-C₄-alkyl, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

30 R⁵⁴ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl and C₁-C₄-alkylen-phenyl, where the phenyl ring may be substituted by up to two radicals R⁵⁹,

35 R⁵⁵ at each occurrence is independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₄-alkylen-phenyl, where the ring may be substituted by up to two radicals R⁶⁰, and OH, O-C₁-C₄-alkyl, O-phenyl, O-C₁-C₄-alkylen-phenyl, NH₂, NH(C₁-C₄-alkyl) and N(C₁-C₄-alkyl)₂,

R^{56} is a group $Q^1-Q^2-Q^3$, where

5 Q^1 is selected from the group consisting of a bond, C_1-C_4 -alkylen, C_2-C_4 -alkenylen,
 C_2-C_4 -alkynylen, C_1-C_4 -alkylen- $N(C_1-C_4$ -alkyl), $N(C_1-C_4$ -alkyl), C_1-C_4 -alkylen- NH ,
 NH , $N(C_1-C_4$ -alkyl)- C_1-C_4 -alkylen, $NH-C_1-C_4$ -alkylen, O , C_1-C_4 -alkylen- O , $O-C_1-C_4$ -
alkylen, $CO-NH$, $CO-N(C_1-C_4$ -alkyl), $NH-CO$, $N(C_1-C_4$ -alkyl)- CO , CO , SO_2 , SO , S ,
 O , SO_2-NH , $SO_2-N(C_1-C_4$ -alkyl), $NH-SO_2$, $N(C_1-C_4$ -alkyl)- SO_2 , $O-CO-NH$, $O-CO-$
10 $N(C_1-C_4$ -alkyl), $NH-CO-O$, $N(C_1-C_4$ -alkyl)- $CO-O$, $N(C_1-C_4$ -alkyl)- $CO-N(C_1-C_4$ -
alkyl), $NH-CO-N(C_1-C_4$ -alkyl), $N(C_1-C_4$ -alkyl)- $CO-NH$, and $NH-CO-NH$,

15 Q^2 is selected from the group consisting of C_1-C_4 -alkylen, C_2-C_4 -alkenylen, C_2-C_4 -
alkynylen, and a bond,

20 Q^3 is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or
tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2
oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups
and may be substituted by the radicals R^{63} , R^{64} and/or R^{65} ,

25 R^{57} at each occurrence is independently selected from the group consisting of
hydrogen, C_1-C_6 -alkyl, phenyl, C_1-C_4 -alkylen-phenyl, $COOH$, $CO-O-C_1-C_4$ -alkyl,
 $CONH_2$, $CO-NH-C_1-C_4$ -alkyl, $CO-N(C_1-C_4$ -alkyl)₂, $CO-C_1-C_4$ -alkyl, CH_2-NH_2 ,
 $CH_2-NH-C_1-C_4$ -alkyl and $CH_2-N(C_1-C_4$ -alkyl)₂,

30 R^{58} at each occurrence is independently selected from the group consisting of
hydrogen, C_1-C_6 -alkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, phenyl and C_1-C_4 -alkylen-
phenyl, where the phenyl ring may be substituted by up to two radicals R^{62} ,

35 R^{59} , R^{60} and R^{62} at each occurrence are selected independently of one another from the
group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN , CF_3 , OCF_3 ,
 NO_2 , OH , $O-C_1-C_4$ -alkyl, C_1-C_6 -alkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, NH_2 , $NH(C_1-C_4$ -
alkyl) and $N(C_1-C_4$ -alkyl)₂,

40 R^{63} , R^{64} and R^{65} at each occurrence are selected independently of one another from the
group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN , CF_3 , OCF_3 ,
 NO_2 , OH , $O-C_1-C_4$ -alkyl, O -phenyl, $O-C_1-C_4$ -alkylen-phenyl, phenyl, C_1-C_6 -alkyl,
 C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, NH_2 , $NH(C_1-C_4$ -alkyl) and $N(C_1-C_4$ -alkyl)₂,

and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof.

7. (Previously Presented) The compound of claim 6, wherein D is selected from the
5 group consisting of aromatic heteromonocyclic and aromatic heterobicyclic systems
comprising 1 or 2 heteroatoms, where one of the 2 heteroatoms is nitrogen.

8. (Previously Presented) The compound of claim 6, wherein D is selected from the
group consisting of benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline,
10 quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene,
benzofuran and furan.

9. (Currently Amended) The compound of ~~any of claims~~ claim 6 [to 8] wherein G is
selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine,
15 pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran,
indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline.

10. (Currently Amended) A [medicament] pharmaceutical composition comprising a
compound as claimed in ~~any of claims~~ claim 1 [to 9] and a pharmaceutically acceptable
20 carrier.

11. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for~~
~~the control and/or prophylaxis of various~~ A method for the therapeutic and/or prophylactic
~~treatment of a mammal having a vasopressin-dependent or oxytocin-dependent [diseases]~~
25 ~~disease comprising administering an effective amount of a compound of claim 1 to a mammal~~
in need of such treatment.

12. (Cancel)

30 13. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for~~
~~the treatment of depressions~~ A method as in claim 11 where the disease is depression and/or a
bipolar [disorders] disorder such as, for example, dysthymic disorders, subsyndromal
depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic
disorders.

35 14. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for~~
~~the treatment of~~ A method as in claim 11 where the disease is anxiety and/or stress-related

disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia.

15. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of A method as in claim 11 where the disease is a memory [disorders] disorder and/or Alzheimer's disease.~~

16. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of psychoses A method as in claim 11 wherein the disease is psychosis and/or a psychotic [disorders] disorder.~~

17. (Currently Amended) ~~The use of a compound as claimed in any of claims 1 to 9 for the treatment of A method as in claim 11 where the disease is [Cushing's] cushing's syndrome.~~

15 18. (New) A pharmaceutical composition comprising a compound as claimed in claim 6 and a pharmaceutically acceptable carrier.

19. (New) A method for the therapeutic and/or prophylactic treatment of a mammal 20 having a vasopressin-dependent or oxytocin-dependent disease comprising administering an effective amount of a compound of claim 6 to a mammal in need of such treatment.

20. (New) A method as in claim 19 where the disease is depression and/or a bipolar disorder such as, for example, dysthymic disorders, subsyndromal depression, seasonal 25 affected disorders, premenstrual dysphoric disorders and/or psychotic disorders.

21. (New) A method as in claim 19 where the disease is anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia.

30 22. (New) A method as in claim 19 where the disease is a memory disorder and/or Alzheimer's disease.

23. (New) A method as in claim 19 wherein the disease is psychosis and/or a psychotic 35 disorder.

24. (New) A method as in claim 19 where the disease is cushing's syndrome.

25. (New) A pharmaceutical composition comprising a compound as claimed in claim 4 and a pharmaceutically acceptable carrier.
26. (New) A method for the therapeutic and/or prophylactic treatment of a mammal
5 having a vasopressin-dependent or oxytocin-dependent disease comprising administering an effective amount of a compound of claim 4 to a mammal in need of such treatment.
27. (New) A method as in claim 26 where the disease is depression and/or a bipolar disorder such as, for example, dysthymic disorders, subsyndromal depression, seasonal
10 affected disorders, premenstrual dysphoric disorders and/or psychotic disorders.
28. (New) A method as in claim 26 where the disease is anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia.
15
29. (New) A method as in claim 26 where the disease is a memory disorder and/or Alzheimer's disease.
30. (New) A method as in claim 26 wherein the disease is psychosis and/or a psychotic
20 disorder.
31. (New) A method as in claim 26 where the disease is cushing's syndrome.